Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

Resources

About Us FAQ Contact Privacy Policy Terms & Conditions Cookie Policy

Today's Highlights

A focused look at the biotech companies and stories making headlines today. Covers noteworthy updates, company-specific developments, and market-relevant activity in a concise format.

1205 Articles

Today's Highlights

View:

Showing 1 to 12 of 1205 articles in Today's Highlights

Today's Highlights

Premium

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...

Prohost Biotech

Mar 31, 2026

Today's Highlights

Premium

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today, March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...

Prohost Biotech

Mar 30, 2026

Today's Highlights

Premium

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...

Prohost Biotech

Mar 27, 2026

Today's Highlights

Premium

Merck to Aquire Terns Pharmaceuticals Expanding Its Hematology Pipeline with Tern-701, A Novel Candidate for Chronic Myeloid Leukemia

Merck & Terns Pharmaceuticals in the NEWS March 25, 2026 (GLOBE NEWSWIRE) -- Merck ( MRK ) - known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) ( TERN ) -...

Prohost Biotech

Mar 25, 2026

Today's Highlights

Premium

Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease

Oryon Cell Therapies Oryon Cell Therapies ( Oryon ) - a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegene...

Prohost Biotech

Mar 23, 2026

Today's Highlights

Premium

Novartis Agrees to Acquire a Pan-Mutant-Selective PI3Kα Inhibitor, Strengthening Its Breast Cancer Pipeline

Novartis in the NEWS Basel, March 20, 2026 – Novartis ( NVS ) today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα...

Prohost Biotech

Mar 20, 2026

Today's Highlights

Premium

FDA Approval of Johnson & Johnson ICOTYDE™ Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis with a Targeted Oral Peptide

Johnson & Johnson in the NEWS March 18, 2026, Johnson & Johnson ( JNJ ) announced today that the FDA has approved ICOTYDE™ ( icotrokinra ), an interleukin-23 ( IL-23 ) receptor antagonist for the trea...

Prohost Biotech

Mar 18, 2026

Today's Highlights

Premium

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer in the NEWS NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. ( PFE ) yesterday announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination wi...

Prohost Biotech

Mar 18, 2026

Today's Highlights

Premium

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics in the NEWS SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) - Structure Therapeutics Inc. ( GPCR ) , today announced positive topline data from the ACCESS clinical program of ale...

Prohost Biotech

Mar 16, 2026

Today's Highlights

Premium

Vertex Pharmaceuticals Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults with IgA Nephropathy

Vertex Pharmaceuticals in the NEWS March 9, 2026, Vertex Pharmaceuticals ( VRTX ) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of po...

Prohost Biotech

Mar 9, 2026

Today's Highlights

Premium

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Intellia Therapeutics March 02, 2026 -- Intellia Therapeutics, Inc. ( NTLA ) , announced that the U.S. FDA has removed the clinical hold on the Investigational New Drug application ( IND ) for the MAG...

Prohost Biotech

Mar 2, 2026

Today's Highlights

Premium

Intellia Therapeutics Announces Q4 and Full-Year 2025 Financial Results and Business Updates

Intellia Therapeutics in the NEWS February 26, 2026, Intellia Therapeutics, Inc. ( NTLA ) , reported business updates and financial results for the fourth quarter and year ended December 31, 2025. Fro...

Prohost Biotech

Feb 26, 2026

Showing 1 to 12 of 1205 results

Prohost BiotechResearch Platform

Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

Articles Categories Tags

Resources

About Us FAQ Contact Privacy Policy Terms & Conditions Cookie Policy